Australia markets close in 16 minutes

Fate Therapeutics, Inc. (FATE)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
4.2700-0.0400 (-0.93%)
At close: 04:00PM EDT
4.2700 0.00 (0.00%)
After hours: 04:02PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.3100
Open4.3500
Bid4.2600 x 800
Ask4.2900 x 2000
Day's range4.1700 - 4.3800
52-week range1.6300 - 8.8300
Volume1,004,212
Avg. volume2,446,578
Market cap486.063M
Beta (5Y monthly)1.90
PE ratio (TTM)N/A
EPS (TTM)-1.9200
Earnings date06 Aug 2024 - 12 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est6.79
  • GlobeNewswire

    Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, July 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on July 1, 2024 the Company granted restricted stock units (RSUs) representing 28,200 shares of its common stock to three newly-hired non-executive employees. The grants were approv

  • GlobeNewswire

    Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference

    SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that the Company will present at the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 3:00 PM ET in New York, New York. A l

  • Insider Monkey

    Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2024 Earnings Call Transcript

    Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2024 Earnings Call Transcript May 11, 2024 Fate Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the Fate Therapeutics First Quarter 2024 Financial Results Conference Call [Operator Instructions]. This call is […]